<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vutrisiran: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vutrisiran: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vutrisiran: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="138973" href="/d/html/138973.html" rel="external">see "Vutrisiran: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56959515"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Amvuttra</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F56918853"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anti-Transthyretin Small Interfering Ribonucleic Acid (siRNA) Agent</li></ul></div>
<div class="block doa drugH1Div" id="F56947455"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Provide vitamin A supplementation at the recommended daily allowance during therapy. If patients develop ocular symptoms consistent with vitamin A deficiency (eg, night blindness), refer to an ophthalmologist.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9da468c6-0590-4353-9e34-3d31c29e8eab">Polyneuropathy associated with hereditary transthyretin-mediated amyloidosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Polyneuropathy associated with hereditary transthyretin-mediated amyloidosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 25 mg once every 3 months.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> Administer as soon as possible after missed dose, then continue dosing every 3 months thereafter.</p></div>
<div class="block dora drugH1Div" id="F56947457"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F56947458"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (total bilirubin ≤1 times the ULN and AST &gt;1 times ULN, or total bilirubin &gt;1 to 1.5 times ULN and any AST): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F56947456"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F56930866"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Neuromuscular &amp; skeletal: Arthralgia (11%), limb pain (15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrioventricular block (2%; including complete atrioventricular block)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Vitamin A deficiency (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (≤4%; including bruising at injection site, erythema at injection site, injection-site pruritus, pain at injection site, warm sensation at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (7%)</p></div>
<div class="block coi drugH1Div" id="F56918856"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F56947444"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Vitamin A: May cause decreased serum vitamin A.</p></div>
<div class="block foc drugH1Div" id="F56959516"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amvuttra: 25 mg/0.5 mL (0.5 mL) [latex free]</p></div>
<div class="block geq drugH1Div" id="F56959514"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F57055668"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Amvuttra Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/0.5 mL (per 0.5 mL): $143,221.20</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F56947459"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;">
<b>SUBQ:</b> Administer by a health care professional. If stored cold, allow syringe to warm to room temperature for 30 minutes prior to use. Inject into abdomen, thighs, or upper arms; do not inject into the 5 cm area around the navel or areas where skin is red, scarred, inflamed, or swollen. Clean planned injection site and uncap needle; a drop of liquid at the tip of the needle is normal. Inject at a 45° to 90° angle into pinched skin. Push plunger rod as far as it will go to inject the full dose and activate plunger needle shield.</p></div>
<div class="block use drugH1Div" id="F56918855"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Polyneuropathy associated with hereditary transthyretin-mediated amyloidosis:</b> Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.</p></div>
<div class="block cyt drugH1Div" id="F56959693"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F56959690"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F56947442"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Vutrisiran decreases serum concentrations of vitamin A, which is required for normal fetal development. The effects to the fetus of maternal vitamin A supplementation during therapy, or the effects to the fetus of reducing maternal serum transthyretin, are not known.</p></div>
<div class="block brc drugH1Div" id="F56947443"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if vutrisiran is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F56947461"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Ocular symptoms suggestive of vitamin A deficiency (eg, night blindness).</p></div>
<div class="block pha drugH1Div" id="F56947447"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Vutrisiran is a double-stranded small interfering ribonucleic acid (siRNA)-N-acetylgalactosamine (GalNAc) conjugate that causes degradation of mutant and wild-type transthyretin (TTR) messenger RNA (mRNA) through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.</p></div>
<div class="block phk drugH1Div" id="F56947448"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~10.1 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 80%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Via endo- and exonucleases; forms short nucleotide fragments of varying sizes within the liver.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~5.2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~19.4% as unchanged drug).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Amvuttra (vutrisiran) [prescribing information]. Cambridge, MA: Alnylam Pharmaceuticals, Inc; June 2022.</div>
</li>
<li>
<div class="reference">
                  Amvuttra (vutrisiran) [prescribing information]. Cambridge, MA: Alnylam Pharmaceuticals, Inc; February 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 138932 Version 26.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
